Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NSA-789 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| placebo | PLACEBO_COMPARATOR | - |
| NSA-789 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| NSA-789 | DRUG | - |
| placebo | OTHER | - |
Inclusion Criteria * Men or women aged 18 - 50 years (healthy subjects) or greater than 55 years old (subjects with Alzheimer's Disease) * Women must be surgically sterile or postmenopausal * Subjects with Alzheimer's Disease must be generally healthy, but may have a stable, chronic illness if well...
Top 20 of 30 competitors
NSA-789 is an investigational small molecule being developed by Pfizer, Inc. for Alzheimer disease. It is in Phase 1 clinical development and is not approved for any indication. The program has completed one Phase 1 trial, a multiple dose study evaluating safety and tolerability.
NSA-789 is being studied for Alzheimer disease, a neurological condition. It is an investigational therapy and has not been approved for the treatment of Alzheimer disease or any other indication. Its only completed clinical trial enrolled healthy subjects and patients with Alzheimer disease.
NSA-789 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the sponsor of the completed Phase 1 study of NSA-789 in Alzheimer disease and healthy subjects.
NSA-789 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The completed study was a randomized, double-blind, placebo-controlled multiple dose study evaluating the safety and tolerability of NSA-789.
NSA-789 has been evaluated in one completed Phase 1 trial, NCT00795730, titled "Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789." The trial enrolled 24 participants in the United States, including healthy volunteers and subjects with Alzheimer disease, and was randomized, double-blind, and placebo-controlled.